Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

NCT03039114

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Banner Health Gilbert, Arizona, United States
  • University of California, San Diego La Jolla, California, United States
  • University of Kansas Cancer Center Fairway, Kansas, United States
  • Center for Cancer and Blood Disorders (CCBD) - Bethesda Bethesda, Maryland, United States
View all 21 locations
View Trial Details
Completed

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04210219

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Arensia Exploratory Medicine Tbilisi, Georgia
  • Arensia Exploratory Medicine Chisinau, Moldova
  • Uniwersyteckie Centrum Kliniczne Gdansk, Poland
View all 15 locations
View Trial Details
Completed

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04657224

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +16 more
Locations
  • Stony Brook University Medical Center Stony Brook, New York, United States
  • Monash Medical Centre Clayton, Australia
  • Peter MacCallum Cancer Centre Melbourne, Australia
  • Linear Clinical Research Ltd Nedlands, Australia
View all 28 locations
View Trial Details
Completed

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

NCT03677154

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham School of Medicine Birmingham, Alabama, United States
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica Santa Monica, California, United States
  • Fort Wayne Medical Institute Fort Wayne, Indiana, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 32 locations
View Trial Details

Related conditions